US EditionAnnovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the successful transfer and rewrite of all its intellectual property protections to cover a newly developed crystalline form of its lead drug candidate, buntanetap. The move solidifies patent coverage for both the original and crystal versions of the compound through 2046. The company originally built its IP portfolio around a semi-crystalline form of buntanetap, targeting chronic neurodegen…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
